Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409351 | 1.00 | CTSK (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2306568 | 1.00 | CTSK (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL863894 | 0.92 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL863895 | 0.92 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3773280 | 0.92 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10606035 | 0.90 | CTSK (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9690449 | 0.90 | ACE (0.48) | CTSKCTSSKLK5FOLH1PPARG | |
| SCHEMBL5129671 | 0.88 | CTSK (0.47) | CTSKCTSSITGB3ITGA2B | |
| SCHEMBL17446712 | 0.88 | CTSL (0.56) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL2301394 | 0.88 | CYP1A2 (0.60) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250382615-A1 | NOVEL RNA THERAPEUTICS AND USES THEREOF | LILLY CO ELI (US) | 2025-12-18 | — | — | US | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4638747-A1 | NOVEL RNA THERAPEUTICS AND USES THEREOF | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638746-A1 | NOVEL RNA THERAPEUTICS AND USES THEREOF | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2025-07-15 | — | — | US | disclosed |
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240327839-A1 | NOVEL THERAPEUTIC DELIVERY MOIETIES AND USES THEREOF | LILLY CO ELI (US) | 2024-10-03 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| CN-1196686-C | Method for storing quaternary ammonium salt | TOKUYAMA CORP (JP) | 2005-04-13 | — | — | CN | disclosed |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1481673-A1 | MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST | Ajinomoto Co., Inc. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2004-08-26 | — | — | US | disclosed |
| CN-1372554-A | Method for preserving quaternary ammonium salts | TOKUYAMA CORP (JP) | 2002-10-02 | — | — | CN | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| CN-1304392-A | Process for producing carboxylic acid derivative and condensing agent comprising quaternary ammonium salt | TOKUYAMA CORP (JP) | 2001-07-18 | — | — | CN | disclosed |
| CN-1169986-A | 2.9-diamino-and 2-amino-8-carbamoyl-4-hydroxy-aldanoic acid amide derivatives | CIBA GEIGY AG (CH) | 1998-01-14 | — | — | CN | disclosed |
| EP-0050799-B1 | NEW PROCESSES FOR THE PRODUCTION OF DI-ALKYL ESTERS AND OPTICALLY ACTIVE MONO-ALKYL ESTERS OF 3-AMINOGLUTARIC ACID | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1984-12-19 | — | — | EP | disclosed |
| EP-0050799-A1 | New processes for the production of di-alkyl esters and optically active mono-alkyl esters of 3-aminoglutaric acid | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | CACNA1B, CACNA1G, CACNA1C | CTSK 3359/4885CTSS 3203/4885CYP1A2 1577/4885 |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | IL2, THPO, IL6 | CTSK 4347/4885CTSS 4585/4885CYP1A2 2815/4885 |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | CACNA1E, CACNA1H, CACNA1D | CTSK 1472/4885CTSS 2672/4885CYP1A2 1285/4885 |
| US-20250382615-A1 | NOVEL RNA THERAPEUTICS AND USES THEREOF | LDLR, TEK, PCSK9 | CTSK 1590/4885CTSS 2552/4885CYP1A2 4809/4885 |
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | FOLR1, FOLR2, FOLH1 | CTSK 936/4885CTSS 446/4885CYP1A2 4628/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | CTSK 3995/4885CTSS 3842/4885CYP1A2 4508/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CTSK 2511/4885CTSS 3101/4885CYP1A2 2422/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | CTSK 2167/4885CTSS 2726/4885CYP1A2 503/4885 |
| US-20240327839-A1 | NOVEL THERAPEUTIC DELIVERY MOIETIES AND USES THEREOF | FABP1, HAVCR2, SLC10A1 | CTSK 2644/4885CTSS 2301/4885CYP1A2 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.